Showing results (81-90 of 164) with videos related to

Sort By:
Pageof 17
Iscience|December 25, 2025
A translational study on the survival and molecular mechanism of PD-L1 expression in EGFR-mutant NSCLC treated with osimertinibShidong Xu, Yangqian Chen, Xing Zhang, et al.
Translational Lung Cancer Research|March 15, 2021
Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancerChuling Li, Meiqi Shi, Xinqing Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|September 18, 2025
Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIsRenzhi Zhang, Huan Yan, Fang Tian, et al.
Translational Lung Cancer Research|May 9, 2022
The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort studyWenjuan Jiang, Yuling Zhou, Liang Zeng, et al.
BMC Cancer|August 3, 2024
Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterationsHaoyue Qin, Huan Yan, Yangqian Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2022
Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective studyWenxian Wang, Gen Lin, Yue Hao, et al.
Journal of Medicinal Chemistry|February 17, 2026
FGF2-Based Cyclic Peptide PET Tracer for Noninvasive Detection of FGFR1 Expression in Non-Small Cell Lung CancerYan Xue, Zhihong Huang, Xue Zhu, et al.
BMC Medicine|October 19, 2021
Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLCYongchang Zhang, Liang Zeng, Xiangyu Zhang, et al.
Frontiers in Oncology|October 18, 2021
A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI ResistanceLi Liu, Jingjing Qu, Jianfu Heng, et al.
BMC Medicine|September 13, 2021
Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective studyYongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, et al.
Pageof 17